Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic <sup>18</sup>F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group

The outcome of high-risk soft tissue sarcoma (STS) is poor with radical surgery being the only potentially curative modality. Pazopanib is a multikinase inhibitor approved for the treatment of metastatic STS. Herein, in terms of the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS) trial, we e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Christos Sachpekidis, Ioannis Karampinis, Jens Jakob, Bernd Kasper, Kai Nowak, Lothar Pilz, Ulrike Attenberger, Timo Gaiser, Hans-Günter Derigs, Matthias Schwarzbach, Peter Hohenberger, Antonia Dimitrakopoulou-Strauss, Ulrich Ronellenfitsch
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2019-06-01
Colecção:Cancers
Assuntos:
soft tissue sarcoma (STS)
pazopanib
dynamic <sup>18</sup>F-FDG PET/CT
SUV
two-tissue compartment model
Acesso em linha:https://www.mdpi.com/2072-6694/11/6/790
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados